A medicine to protect the heart during breast cancer chemotherapy
Part of Brain & nervous system, Cancer, Heart & circulation clinical trials.
This early-phase study tests azeliragon to lower the risk of chemotherapy-related heart damage in women with early-stage breast cancer. Participants get their planned standard chemotherapy, plus the study medicine, and are monitored for safety and heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have stage I–III breast cancer and be scheduled for chemotherapy before or after surgery (adjuvant or neoadjuvant)
- Have not had any prior chemo, radiation, or other cancer treatment for early breast cancer (or any other cancer)
- Be age 18 or older, and generally well enough to do daily activities (performance status 0–2)
- Have blood counts and organ tests that are in acceptable ranges (kidney, liver, and bone marrow)
- Be able to use effective birth control during the study, and not be pregnant or breastfeeding
- Not take certain medicines that strongly interact with the study drug (especially strong CYP2C8 inhibitors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine called pentoxifylline can help prevent heart damage caused by doxorubicin, a common chemotherapy drug for breast cancer. If you are starting doxorubicin for the first time, this study may offer added heart protection.
This trial tests whether grape polyphenols can help protect the heart in women being treated for breast cancer with certain chemotherapy drugs that can harm the heart. If you are at high risk for heart problems from chemo, this study may offer a way to reduce that risk.
This trial tests whether two different medications (SGLT-2 inhibitor vs. DPP-4 inhibitor) can help prevent heart damage from certain chemotherapy drugs (anthracyclines) in women with breast cancer. It aims to protect your heart while you undergo cancer treatment.
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
This trial tests if telmisartan, a blood pressure medicine, can protect the heart from damage caused by the chemotherapy drug doxorubicin in women with breast cancer.
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
Hear when a new Non-metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.